EXEL vs TWST
Exelixis vs Twist Bioscience Corporation — AI-powered side-by-side comparison
VS
TWST
Twist Bioscience Corporation
60
Buy
| Metric | EXEL | TWST |
|---|
| AI Score |
67
|
60
|
| Price |
$51.30
|
$123.08
|
| P/E Ratio |
15.60×
|
-55.46×
|
| ROE |
36.2%
|
-16.4%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
96.5%
|
52.0%
|
| Debt / Equity |
0.09×
|
0.21×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
41.0
|
74.5
|
| Beta |
0.422
|
2.158
|
| Expected Upside |
+8.7%
|
—
|
AI Committee View
Current Innellis committee reasoning for EXEL versus TWST.
EXEL leads by 7 points.
EXEL scores 67/100 (Buy) versus TWST at 60/100 (Buy).
EXEL Committee View
67% agreement
6 analysts
The primary driver is low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock. The main limiting factor is price-to-book of 5.4x prices in significant intangible value. The committee is constructive but not yet at full conviction.
Bull Case
- ROE of 42.5% shows genuine earnings power backing the valuation — Value
- EPS growing 52.7% YoY — Growth
- 5 consecutive earnings beats -- consistent execution — Growth
Bear Case
- Price-to-book of 5.4x prices in significant intangible value — Value
- MACD histogram negative -- bearish momentum — Technical
TWST Committee View
75% agreement
4 analysts
The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Risk Analyst remains cautious — bollinger bandwidth of 49.8% signals elevated volatility. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- RSI at 75 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
- Weekly RSI at 84 -- overbought on the larger timeframe too — Technical